Display options
Cite
Serrano-Novillo C, Capera J, Colomer-Molera M, et al. Implication of Voltage-Gated Potassium Channels in Neoplastic Cell Proliferation. Cancers (Basel). 2019;11(3)doi: 10.3390/cancers11030287.
Serrano-Novillo, C., Capera, J., Colomer-Molera, M., Condom, E., Ferreres, J. C., & Felipe, A. (2019). Implication of Voltage-Gated Potassium Channels in Neoplastic Cell Proliferation. Cancers, 11(3), . https://doi.org/10.3390/cancers11030287
Serrano-Novillo, Clara, et al. "Implication of Voltage-Gated Potassium Channels in Neoplastic Cell Proliferation." Cancers vol. 11,3 (2019). doi: https://doi.org/10.3390/cancers11030287
Serrano-Novillo C, Capera J, Colomer-Molera M, Condom E, Ferreres JC, Felipe A. Implication of Voltage-Gated Potassium Channels in Neoplastic Cell Proliferation. Cancers (Basel). 2019 Mar 01;11(3). doi: 10.3390/cancers11030287. PMID: 30823672; PMCID: PMC6468671.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2019 Mar 01;11(3). doi: 10.3390/cancers11030287.

Implication of Voltage-Gated Potassium Channels in Neoplastic Cell Proliferation.

Cancers

Clara Serrano-Novillo, Jesusa Capera, Magalí Colomer-Molera, Enric Condom, Joan Carles Ferreres, Antonio Felipe

Affiliations

  1. Molecular Physiology Laboratory, Departament de Bioquímica i Biomedicina Molecular, Institut de Biomedicina (IBUB), Universitat de Barcelona, Avda. Diagonal 643, E-08028 Barcelona, Spain. [email protected].
  2. Molecular Physiology Laboratory, Departament de Bioquímica i Biomedicina Molecular, Institut de Biomedicina (IBUB), Universitat de Barcelona, Avda. Diagonal 643, E-08028 Barcelona, Spain. [email protected].
  3. Molecular Physiology Laboratory, Departament de Bioquímica i Biomedicina Molecular, Institut de Biomedicina (IBUB), Universitat de Barcelona, Avda. Diagonal 643, E-08028 Barcelona, Spain. [email protected].
  4. Departament de Patologia i Terapèutica Experimental, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. [email protected].
  5. Departament de Ciències Morfològiques, Parc Taulí Hospital Universitari, Universitat Autònoma de Barcelona, 08208 Barcelona, Spain. [email protected].
  6. Molecular Physiology Laboratory, Departament de Bioquímica i Biomedicina Molecular, Institut de Biomedicina (IBUB), Universitat de Barcelona, Avda. Diagonal 643, E-08028 Barcelona, Spain. [email protected].

PMID: 30823672 PMCID: PMC6468671 DOI: 10.3390/cancers11030287

Abstract

Voltage-gated potassium channels (Kv) are the largest group of ion channels. Kv are involved in controlling the resting potential and action potential duration in the heart and brain. Additionally, these proteins participate in cell cycle progression as well as in several other important features in mammalian cell physiology, such as activation, differentiation, apoptosis, and cell volume control. Therefore, Kv remarkably participate in the cell function by balancing responses. The implication of Kv in physiological and pathophysiological cell growth is the subject of study, as Kv are proposed as therapeutic targets for tumor regression. Though it is widely accepted that Kv channels control proliferation by allowing cell cycle progression, their role is controversial. Kv expression is altered in many cancers, and their participation, as well as their use as tumor markers, is worthy of effort. There is an ever-growing list of Kv that remodel during tumorigenesis. This review focuses on the actual knowledge of Kv channel expression and their relationship with neoplastic proliferation. In this work, we provide an update of what is currently known about these proteins, thereby paving the way for a more precise understanding of the participation of Kv during cancer development.

Keywords: K+ channels; cancer; cell cycle; proliferation; tumor progression

References

  1. J Neurosci. 1999 Jul 1;19(13):5380-92 - PubMed
  2. EMBO J. 1999 Oct 15;18(20):5540-7 - PubMed
  3. Glia. 2000 Mar;30(1):39-48 - PubMed
  4. Br J Cancer. 2000 Dec;83(12):1722-9 - PubMed
  5. Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2350-5 - PubMed
  6. J Biol Chem. 2002 May 24;277(21):18528-34 - PubMed
  7. Biochem Biophys Res Commun. 2002 Jul 12;295(2):526-31 - PubMed
  8. Cancer Lett. 2002 Dec 1;186(1):99-105 - PubMed
  9. Neurosci Lett. 2003 Jul 31;346(1-2):33-6 - PubMed
  10. J Biol Chem. 2003 Nov 21;278(47):46307-20 - PubMed
  11. Gan. 1957 Dec;48(4):353-4 - PubMed
  12. Eur Biophys J. 2004 May;33(3):227-32 - PubMed
  13. J Oral Pathol Med. 2003 Nov;32(10):606-11 - PubMed
  14. Cancer Res. 2004 Jan 15;64(2):606-11 - PubMed
  15. Pflugers Arch. 2004 Jun;448(3):274-86 - PubMed
  16. Int J Oncol. 2004 Jul;25(1):153-9 - PubMed
  17. J Oral Pathol Med. 2004 Oct;33(9):543-9 - PubMed
  18. Physiology (Bethesda). 2004 Oct;19:285-92 - PubMed
  19. J Cell Physiol. 2005 Feb;202(2):400-10 - PubMed
  20. Sci STKE. 2004 Oct 05;2004(253):re15 - PubMed
  21. J Immunol. 2005 Apr 15;174(8):4736-44 - PubMed
  22. J Clin Invest. 2005 Aug;115(8):1986-9 - PubMed
  23. Cancer Biol Ther. 2005 Dec;4(12):1342-7 - PubMed
  24. J Membr Biol. 2005 Jun;205(3):159-73 - PubMed
  25. Pharmacol Rev. 2005 Dec;57(4):473-508 - PubMed
  26. Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2886-91 - PubMed
  27. Cancer Detect Prev. 2006;30(4):375-85 - PubMed
  28. Mol Cancer. 2006 Oct 05;5:41 - PubMed
  29. Clin Cancer Res. 2007 Feb 1;13(3):824-31 - PubMed
  30. Blood. 2007 Aug 15;110(4):1238-50 - PubMed
  31. J Membr Biol. 2006;214(2):99-102 - PubMed
  32. Life Sci. 2007 Jun 27;81(3):255-65 - PubMed
  33. Med Oncol. 2007;24(3):345-50 - PubMed
  34. Methods Enzymol. 2007;428:209-25 - PubMed
  35. Cell Prolif. 2007 Oct;40(5):656-70 - PubMed
  36. Nat Rev Cancer. 2007 Nov;7(11):834-46 - PubMed
  37. J Biol Chem. 2008 Mar 28;283(13):8756-64 - PubMed
  38. Recent Pat Anticancer Drug Discov. 2007 Nov;2(3):212-23 - PubMed
  39. Biochim Biophys Acta. 2008 May;1783(5):728-36 - PubMed
  40. Biochem Biophys Res Commun. 2008 May 16;369(4):1094-7 - PubMed
  41. Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14861-6 - PubMed
  42. J Biol Chem. 2008 Dec 26;283(52):36234-40 - PubMed
  43. Curr Med Chem. 2009;16(1):66-93 - PubMed
  44. Biochem Biophys Res Commun. 2009 Jun 26;384(2):180-6 - PubMed
  45. Pancreas. 2009 Aug;38(6):649-54 - PubMed
  46. Dig Dis Sci. 2010 Apr;55(4):1004-10 - PubMed
  47. Cell Physiol Biochem. 2009;24(1-2):25-32 - PubMed
  48. BMB Rep. 2009 Aug 31;42(8):535-9 - PubMed
  49. Cell Cycle. 2009 Nov 1;8(21):3527-36 - PubMed
  50. Curr Cancer Drug Targets. 2009 Dec;9(8):904-14 - PubMed
  51. Mol Cancer. 2010 Jan 27;9:18 - PubMed
  52. Eur J Cancer. 2010 May;46(7):1181-8 - PubMed
  53. J Pathol. 2010 Aug;221(4):402-10 - PubMed
  54. Biol Pharm Bull. 2010;33(10):1754-7 - PubMed
  55. Clin Biochem. 2011 Dec;44(17-18):1405-11 - PubMed
  56. Pain. 2012 Mar;153(3):562-74 - PubMed
  57. Curr Med Chem. 2012;19(5):661-74 - PubMed
  58. Cancer Invest. 2012 Mar;30(3):203-8 - PubMed
  59. Arterioscler Thromb Vasc Biol. 2012 May;32(5):1299-307 - PubMed
  60. J Biol Chem. 2012 Jul 13;287(29):24754-64 - PubMed
  61. Oncol Lett. 2012 Aug;4(2):227-230 - PubMed
  62. PLoS One. 2012;7(11):e49758 - PubMed
  63. Leukemia. 2013 Aug;27(8):1782-5 - PubMed
  64. Radiol Oncol. 2013 Mar;47(1):42-9 - PubMed
  65. Cancer Res. 2013 Aug 15;73(16):5253-65 - PubMed
  66. J Leukoc Biol. 2013 Oct;94(4):779-89 - PubMed
  67. Front Physiol. 2013 Jul 17;4:185 - PubMed
  68. PLoS One. 2013 Aug 02;8(8):e72409 - PubMed
  69. Pflugers Arch. 2014 Mar;466(3):541-8 - PubMed
  70. Int J Mol Sci. 2013 Sep 23;14(9):19245-56 - PubMed
  71. Front Physiol. 2013 Oct 10;4:283 - PubMed
  72. Sci Rep. 2013 Nov 25;3:3308 - PubMed
  73. Nat Rev Cancer. 2014 Jan;14(1):39-48 - PubMed
  74. Clin Cancer Res. 2014 Mar 15;20(6):1502-12 - PubMed
  75. Oncogene. 2014 Dec 4;33(49):5569-81 - PubMed
  76. Philos Trans R Soc Lond B Biol Sci. 2014 Feb 03;369(1638):20130094 - PubMed
  77. Endocr J. 2014;61(6):597-605 - PubMed
  78. Int J Mol Sci. 2014 Apr 01;15(4):5570-81 - PubMed
  79. BMJ Open. 2014 May 16;4(5):e005049 - PubMed
  80. Annu Rev Physiol. 2015;77:505-24 - PubMed
  81. Oncogene. 2015 Aug 27;34(35):4591-600 - PubMed
  82. Br J Cancer. 2015 Mar 17;112(6):1076-87 - PubMed
  83. J Cell Sci. 2015 Jun 1;128(11):2096-105 - PubMed
  84. Oncotarget. 2015 Apr 10;6(10):8132-43 - PubMed
  85. Cell Physiol Biochem. 2015;37(3):965-78 - PubMed
  86. J Biol Chem. 2015 Dec 4;290(49):29189-201 - PubMed
  87. BMC Cancer. 2015 Nov 03;15:839 - PubMed
  88. Int J Mol Sci. 2015 Nov 11;16(11):26914-26 - PubMed
  89. Mol Cancer Res. 2016 Jan;14(1):26-34 - PubMed
  90. Histopathology. 2016 Jul;69(1):91-8 - PubMed
  91. J Biol Chem. 2016 Feb 12;291(7):3569-80 - PubMed
  92. J Gen Physiol. 2016 Feb;147(2):105-25 - PubMed
  93. Pharmacol Rep. 2016 Apr;68(2):457-61 - PubMed
  94. Cell Cycle. 2016;15(6):799-811 - PubMed
  95. EMBO Rep. 2016 May;17(5):708-23 - PubMed
  96. Oncotarget. 2017 Jun 13;8(24):38276-38293 - PubMed
  97. Bioessays. 2017 Jun;39(6): - PubMed
  98. Cancer Cell. 2017 Apr 10;31(4):516-531.e10 - PubMed
  99. Discov Med. 2017 Mar;23(126):155-162 - PubMed
  100. Neurosignals. 2017;25(1):26-38 - PubMed
  101. Front Oncol. 2017 Sep 29;7:239 - PubMed
  102. Int J Biol Macromol. 2018 May;111:1146-1155 - PubMed
  103. Int J Mol Sci. 2018 Apr 02;19(4):null - PubMed
  104. Cancer Cell Int. 2018 Jul 5;18:93 - PubMed
  105. Int J Mol Sci. 2018 Jul 15;19(7):null - PubMed
  106. J Theor Biol. 1971 Jan;30(1):151-81 - PubMed
  107. J Physiol. 1995 Dec 1;489 ( Pt 2):455-71 - PubMed
  108. Cancer Res. 1998 Feb 15;58(4):815-22 - PubMed
  109. J Physiol. 1998 Apr 1;508 ( Pt 1):49-56 - PubMed
  110. J Physiol. 1998 Jul 1;510 ( Pt 1):93-102 - PubMed

Publication Types

Grant support